Teva undeterred by Mylan rejection

Teva CEO Erez Vigodman bypasses Mylan's board and appeals directly to its shareholders.

Erez Vigodman,   Teva

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) is undeterred by the rejection of its bid for Mylan N.V. (Nasdaq: MYL).

Teva president and CEO Erez Vigodman said, “While we are disappointed that Mylan has formally rejected our proposal, the Teva Board and management team are fully committed to completing the combination of Teva and Mylan, and we stand ready to quickly complete a transaction that is compelling for both Teva and Mylan stockholders. We are eager to work with Mylan and its advisors to complete a transaction that will allow us to deliver the value inherent in the proposed combination to our respective stockholders, employees, patients, customers, communities and other stakeholders.”…


Published by Globes [online], Israel business news –

Read more about: , , , , , , , , ,

Wordpress site Developed by Fixing WordPress Problems